Company Overview - The company, Shanghai Jianhui Information Technology Co., Ltd., focuses on providing intelligent management solutions for the pharmaceutical and medical service industries [1] - Main products include smart pharmacy projects, intelligent central preparation centers, intelligent drug consumables management, logistics and mobile robotics projects, maintenance services, and other business revenues [1] Financial Performance - For Q1 2025, the company reported revenue of 77.06 million yuan, a year-on-year increase of 116.27% [1] - Net profit for the same period was 3.43 million yuan, showing a year-on-year decrease of 34.65% [1] - The gross profit margin was reported at 37.17% [1] Market Position - The company's stock closed at 22.66 yuan, with a PE ratio of 100.37, marking a new low in 11 days [1] - The total market capitalization is 3.082 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 47.79, with a median of 59.03, placing the company at 38th in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 16,423, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1: Industry Overview - The domestic preclinical CRO, clinical CRO, and CDMO business prices have stabilized, with new orders gradually recovering, indicating a potential industry turnaround [1] - In the international CDMO sector, the pricing system remains reasonable, and the impact of high pandemic baselines has been absorbed [1] - Chinese companies possess comprehensive advantages in small molecule CRDMO due to talent dividends, chemical capabilities, compliant production capacity, and intellectual property protection [1] Group 2: Large Molecule CDMO - Major domestic companies include WuXi Biologics and WuXi AppTec, while international players include Lonza, Samsung Biologics, and Fujifilm [2] - Samsung Biologics is expected to have a revenue growth rate of 19-25% for 2024, surpassing WuXi Biologics' guidance of 12-15% [2] - The order growth for Samsung Biologics exceeds that of WuXi Biologics, indicating intense competition in the large molecule CDMO sector [2] Group 3: Small Molecule CDMO - Key domestic companies include WuXi AppTec, Kelun Pharmaceutical, and Boteng Pharmaceuticals, with over 70% of their business overseas [3] - WuXi AppTec's order backlog is expected to grow by 47% year-on-year by the end of 2024, ensuring mid-term performance [3] - Capital expenditure among domestic companies shows divergence, with some leaders like WuXi AppTec expected to increase spending [3] Group 4: Clinical/Preclinical CRO - Major domestic companies include Tigermed, Pruis, and Medpace, with a high proportion of domestic business [4] - Both domestic and international CROs are currently in an adjustment phase, with 2022-2023 funding challenges impacting 2024 performance [4] - Domestic order prices have bottomed out, with a growth trend in order volume and value since 2025 [5]

Core Viewpoints - The employment data has severely impacted market confidence, leading to declines in major indices such as the Hang Seng Index, which fell by 1.07% [2] - The market is experiencing a significant sell-off, with a notable increase in short-selling activity, indicating a bearish sentiment among investors [2][4] Company Overview - The specific company under review, Zhonghui Biotech, was established in 2015 and focuses on the development of innovative vaccines, including a quadrivalent influenza vaccine and a freeze-dried rabies vaccine [10] - The quadrivalent influenza vaccine was launched in May 2023, marking it as the first and only approved vaccine of its kind in China [10] - The company is currently in a loss-making position, with projected revenues of 52.2 million and 259.6 million for 2023 and 2024 respectively, while total losses are expected to reach 424.7 million and 258.7 million for the same years [10] Industry Status and Outlook - The Chinese human vaccine market is projected to grow significantly, from 53.5 billion in 2019 to 96.1 billion by 2024, with a CAGR of 12.4% [11] - By 2033, the market is expected to reach 331.9 billion, driven by technological advancements, increased public awareness of vaccination, and supportive preventive healthcare policies [11] Advantages and Opportunities - The company has the potential to address unmet needs in the high-quality vaccine market with its quadrivalent influenza vaccine, which offers higher safety and better immune response [12] - A leading R&D technology platform supports the development of its vaccine pipeline, which includes 11 additional vaccines currently in research [12] Fundraising and Use of Proceeds - The IPO is set to raise funds with approximately 63.6% allocated for the development and registration of core products, while 18.1% will be used for other vaccine developments [16] - The remaining funds will enhance production capabilities and support operational costs [16] Investment Recommendation - The IPO price range is set between 12.9 and 15.5 HKD, with a post-IPO market capitalization estimated at 50.75 to 60.98 billion HKD [17] - The valuation appears high when compared to peers, with a projected PS ratio of 17.9 to 21.6 for 2024 [17]

Investment Rating - The investment rating for the CXO industry is "Outperform the Market" [1] Core Insights - The CXO index has increased by over 50% in the past year due to the easing of geopolitical risks, recovery in investment, and the digestion of high pandemic baselines [2] - Chinese CXO companies are analyzed from short-term, medium-term, and long-term perspectives to understand their global competitiveness [2] - Major players in the large molecule CDMO sector include WuXi Biologics and WuXi AppTec, with over 70% of their revenue coming from overseas [2] - The small molecule CDMO sector shows strong recovery in domestic companies, with significant order growth and a favorable competitive landscape [2] - Clinical and preclinical CROs are currently in an adjustment phase, with domestic order prices stabilizing but showing no significant recovery [2] Summary by Sections Large Molecule CDMO - Short-term performance shows high growth with competition from Japan, South Korea, and Europe [2] - Medium-term order growth is led by South Korean companies like Samsung Biologics, indicating intense competition for Chinese firms [2] - Long-term capital expenditures remain high, reflecting confidence in future demand [2] Small Molecule CDMO - Domestic companies are recovering from pandemic-related performance dips, with overall growth expected in 2025 [2] - Order growth is robust, with WuXi AppTec's orders increasing by 47% year-on-year by the end of 2024 [2] - Long-term capital expenditures show divergence, with some leaders like WuXi AppTec expected to continue increasing investments [2] Clinical/Preclinical CRO - Both domestic and international CROs are in an adjustment period, with 2022-2023 investment cooling reflected in 2024 performance [2] - Medium-term order volumes and values are beginning to show growth, while international orders remain stable [2] - Long-term capital expenditures vary among companies, indicating potential supply-demand mismatches in the short term [2] Emerging Business Opportunities - Rapid development in new molecular businesses such as peptides and oligonucleotides is expected to open up growth opportunities in the CXO sector [3] - Generic drug CROs are actively pursuing innovative transformations to seek new growth points [3]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Viewpoints - The report highlights that the demand for hepatitis B cure remains a blue ocean, with CpAMs and small nucleic acid drugs expected to lead the way in achieving functional cures. The large base of hepatitis B infections in China and the limitations of existing therapies create a pressing need for effective treatments [4][15] - The implementation of the "Childcare Subsidy System" is expected to enhance the willingness of families to have children, positively impacting related sectors such as pediatric medicine, medical equipment, and maternal health services [6][21][23] - The pharmaceutical sector saw an overall increase of 2.95% this week, outperforming the CSI 300 index by 4.70 percentage points, with the chemical preparation sector showing the highest growth at 5.48% [25][26] Summary by Sections 1. Hepatitis B Treatment Opportunities - The report emphasizes the significant unmet need for hepatitis B cures in China, with approximately 56 million chronic carriers and a high percentage at risk of severe liver disease [15] - Current approved treatments are limited, with nucleos(t)ide analogs (NAs) and pegylated interferon-α showing inadequate rates of functional cure [15][16] - New drug classes, including CpAMs and small nucleic acids, are in advanced clinical stages, with companies like GSK and AHB-137 leading the way [17][18] 2. Childcare Subsidy System - The newly announced childcare subsidy will provide annual financial support of 3,600 yuan per child under three years old, starting from January 1, 2025 [21][22] - This initiative is expected to boost sectors related to child healthcare and maternal services, enhancing market opportunities for companies in these fields [23][24] 3. Weekly Performance of Pharmaceutical Sector - The pharmaceutical sector's performance this week was marked by a 2.95% increase, with the chemical preparation sector leading at 5.48% [25][26] - The report notes a significant divergence in performance among sub-sectors, with medical devices experiencing a decline of 1.43% [26][32] 4. Beneficiary Stocks - The report identifies several beneficiary stocks across various segments, including innovative drugs (e.g., Innovent Biologics, BeiGene), traditional Chinese medicine (e.g., Jiuzhitang), and medical devices (e.g., Mindray Medical) [8][9][33][40] 5. Market Outlook - The report suggests a positive outlook for innovative drugs driven by overseas expansion and supportive policy developments, with a focus on companies with strong clinical data and market potential [31] - The medical device sector is expected to benefit from upcoming procurement policies and a recovery in demand, particularly for high-end equipment [32][33]

Group 1 - The core viewpoint of the articles highlights Chengdu Xian Dao's current market performance, with a closing price of 23.83 yuan and a rolling PE ratio of 145.33 times, significantly higher than the industry average of 47.90 times [1][2] - Chengdu Xian Dao's total market capitalization is reported at 9.548 billion yuan, ranking 40th in the medical services industry based on PE ratio [1][2] - The company specializes in drug development services related to DEL technology, offering services such as DEL screening, custom DEL libraries, FBDD/SBDD, custom new drug development, and chemical synthesis [1] Group 2 - For the first quarter of 2025, the company reported an operating income of 107 million yuan, a year-on-year decrease of 0.60%, while net profit increased by 102.90% to 28.2844 million yuan, with a gross margin of 51.87% [2] - As of the first quarter of 2025, only one institution holds shares in Chengdu Xian Dao, with a total of 357,100 shares valued at 0.06 million yuan [1] - The company has obtained 138 invention patents and 13 software copyrights, with over 300 additional patents pending, showcasing its extensive research and development efforts in the DEL technology field [1]

Core Viewpoint - The article highlights the rapid response and collaboration between Beijing Yicheng Foundation and Kanglong Chemical to provide essential supplies to areas affected by severe rainstorms in Beijing and Hebei, showcasing the effectiveness of public-private partnerships in disaster relief efforts [2][4]. Group 1: Emergency Response - The first batch of relief supplies, funded by donations, was delivered to the emergency areas in Miyun and Huairou districts within 48 hours, demonstrating a highly efficient "donation-procurement-shipment" model [2]. - The supplies included essential items such as toilet paper, rain boots, flashlights, drinking water, and portable gasoline generators, which were identified through a digital procurement platform [2][4]. Group 2: Organizational Collaboration - The rapid delivery of supplies filled local emergency needs and encouraged more companies in the Beijing Economic-Technological Development Area to participate in the relief efforts [4]. - The Yicheng Foundation has established a special donation channel to continuously gather support from businesses and the community for ongoing assistance to the disaster-stricken areas [4]. Group 3: Transparency and Accountability - The Yicheng Foundation utilized digital tools to ensure transparent management of the donation process, allowing for traceability and supervision of fund usage, which sets a standard for efficient disaster relief [4]. - The foundation has implemented over 200 projects in emergency relief and technology education, emphasizing its commitment to building a collaborative platform among enterprises, society, and government [4].

Core Viewpoint - The company announced that one of its actual controllers, Ms. Zheng Bei, has pledged and subsequently released a portion of her shares in the company [1] Summary by Relevant Sections - Share Pledge: On July 30, 2025, Ms. Zheng pledged 7.35 million shares [1] - Share Release: On July 31, 2025, Ms. Zheng released 7.61 million shares from the pledge [1]

于2025年7月30日，郑北质押735万股股份。2025年7月31日，郑北解除质押761万股股份。 康龙化成（300759）(03759)公布，公司近日接到公司实际控制人之一郑北女士的函告，获悉郑北女士 将其所持有的公司部分股份进行了质押和解除质押。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年8月1日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 证券代码：300759 证券简称：康龙化成 公告编号：2025-039 康龙化成（北京）新药技术股份有限公司 关于 ...